Linked from

The 21 pages that link to CYP3A4, each with the reason it gives.

• CarbamazepineRelated: CYP3A4 converts carbamazepine to its active epoxide metabolite.

• AmlodipineRelated: CYP3A4 inhibitors can raise amlodipine exposure, while inducers may lower it.

• AripiprazoleRelated: CYP3A4 contributes to aripiprazole metabolism and creates clinically relevant interaction risks.

• Statin-associated muscle symptomsRelated: Inhibiting this enzyme can raise concentrations of certain statins and increase muscle risk.

• MidazolamRelated: CYP3A4 metabolizes midazolam, so inhibitors and inducers can substantially alter its exposure.

• VerapamilRelated: Verapamil is metabolized by and can inhibit CYP3A4, creating clinically relevant drug interactions.

• LoratadineRelated: CYP3A4 contributes to loratadine metabolism and can be inhibited by interacting drugs.

• ClarithromycinRelated: Clarithromycin inhibits CYP3A4, raising concentrations of some co-administered medicines.

• DiltiazemRelated: Diltiazem inhibits CYP3A4, which can raise levels of interacting drugs.

• RitonavirRelated: Ritonavir inhibits CYP3A4, slowing the breakdown of co-administered antivirals.

• ApixabanRelated: Strong CYP3A4 inhibitors or inducers can affect apixaban exposure and prescribing.

• DomperidoneRelated: Strong CYP3A4 inhibitors can increase domperidone exposure and heighten cardiac risk.

• VardenafilRelated: Strong CYP3A4 inhibitors can raise vardenafil exposure and adverse-effect risk.

• ErgotamineRelated: Strong CYP3A4 inhibitors can sharply increase ergotamine exposure and cause severe vasospasm.

• RivaroxabanRelated: It contributes to rivaroxaban metabolism and helps explain some drug interactions.

• TriazolamRelated: CYP3A4 inhibitors can raise triazolam exposure and intensify its sedative effects.

• CiclosporinRelated: CYP3A4 metabolizes ciclosporin and contributes to its many drug interactions.